New nanoparticle treatment for drug-resistant lung cancer
Towards Translation of MU-CN29: New Therapeutic Nanoparticle for Drug-Resistant NSCLC
This study is testing a new treatment called MU-CN29 to help people with non-small cell lung cancer who have EGFR mutations and are struggling with standard therapies, aiming to make those treatments work better and improve survival.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-11093496 on NIH RePORTER |
What this research studies
This research focuses on developing a novel therapeutic nanoparticle, MU-CN29, aimed at overcoming drug resistance in non-small cell lung cancer (NSCLC) patients with EGFR mutations. The approach involves targeting specific molecular pathways that contribute to resistance against standard treatments, such as tyrosine kinase inhibitors. By restoring sensitivity to these treatments and enhancing the immune response, the research aims to improve survival rates for patients who currently have limited options. The study will utilize both laboratory and animal models to evaluate the effectiveness of MU-CN29.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have EGFR mutations and have developed resistance to standard therapies.
Not a fit: Patients with non-small cell lung cancer who do not have EGFR mutations or those who have not developed resistance to current treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that significantly improves survival rates for patients with drug-resistant NSCLC.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in drug-resistant cancers, indicating potential for success with this novel approach.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Kannan, Raghuraman — University of Missouri-Columbia
- Study coordinator: Kannan, Raghuraman
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.